Abstract: The Undersea and Hyperbaric Medical Society includes "select problem wounds" as an accepted indication for the use of hyperbaric oxygen (HBO 2 ), however, the treatment of diabetic foot ulcers (DFUs) has dominated any discussions of problem wounds because of the prevalence of DFUs in today's patient population and the reimbursement available for their treatment. Other wound types (eg, calciphylaxis ulcers, sickle cell ulcers, and pyoderma gangrenosum) that have well-deserved reputations as problem wounds have been infrequently treated with HBO 2 . While there are sound fundamental reasons why additional oxygen may have benefits in the treatment of these wounds, the challenge is finding enough high quality evidence to support routine use of HBO 2 . Keywords: hyperbaric oxygen therapy, HBO 2 , oxygen, problem wounds, chronic wounds, wound healing, diabetic foot ulcers, arterial insufficiency ulcers, sickle cell disease, scleroderma, calciphylaxis, graft versus host disease, pyoderma gangrenosum, venous stasis ulcers
The role of oxygen in wound healing
Oxygen is involved in nearly every phase of wound healing, acting as a critical cofactor for fibroblast replication, collagen deposition, 1 angiogenesis, [2] [3] [4] [5] resistance to infection, [6] [7] [8] and intracellular leukocyte bacterial killing. 6 Tissue hypoxia, on the other hand, is the initiator of wound healing and leads to upregulation of hypoxiainducible factors (HIFs) that play a central role in adapting the body to a hypoxic environment. These adaptions include angiogenesis, anaerobic glycolysis, cellular mobility, growth factor signaling, and erythropoiesis. 9 Wounds become hypoxic as a result of acute or chronic injury. Hemostasis is the first phase of wound healing. Vasoconstriction, platelet aggregation, and formation of a fibrin clot stop bleeding but also cause local ischemia and hypoxia as vessels thrombose. 10 Wound hypoxia is exacerbated by underlying conditions that result in decreased perfusion to the wound (eg, decreased cardiac output, increased peripheral vascular resistance, and presence of peripheral arterial disease [PAD] or pulmonary dysfunction). Oxygen carrying capacity is determined by the hemoglobin dissociation curve. Although anemia results in decreased overall O 2 carrying capacity, it does not inherently inhibit wound healing. 11 Arterial pO 2 is the key factor in wound healing potential and can be modulated through vasodilation, improved cardiac output, capillary permeability, and increased alveolar pO 2 achieved under hyperbaric conditions.
The inflammatory phase begins a few days after injury as neutrophils and monocytes begin the process of breaking down and clearing cellular debris. 10 Macrophages take the lead in breaking down devitalized tissue and killing bacteria, 10, 12 however, oxidative killing is depressed in patients with local wound hypoxia. A minimum tissue pO 2 of 30 mmHg is required for effective bacterial killing. 7 Neutrophils killed 37% of organisms in 1 hour under anoxic conditions, 58% when pO 2 was raised to 5 mmHg, and 70% at 30 mmHg. There was a minimal increase in killing efficiency when tissue pO 2 was further increased to 150 mmHg. 13 Neutrophil bacterial killing activity depends on an oxygen-dependent respiratory burst where neutrophils convert oxygen to superoxide. 14 This process can result in a 20-100 fold increase in oxygen consumption 15, 16 and a decrease in tissue pO 2 from 60 mmHg down to 0-10 mmHg. 17 Superoxide production is at its maximal rate at a tissue pO 2 of 300 mmHg but is cut in half with tissue pO 2 between 80-150 mmHg. 18 There is synergy between antibiotic administration and hyperoxia, as early antibiotic administration combined with hyperoxia resulted in more efficient bacterial clearance than delayed administration of either antibiotics or oxygen. 8 Higher inspired oxygen has also been shown to decrease the spread of infectious necrosis. 6 The proliferative phase of wound healing sees an increase in collagen deposition, angiogenesis, granulation tissue formation, and epithelialization, 10 20, 27, 28 Remodeling is the final phase of wound healing and occurs weeks to months after a wound is epithelialized. Immature collagen, which is thinner than mature collagen and deposited parallel to the skin, 29 is reorganized into a more structurally sound lattice. Cross-linking of collagen fibers increases wound strength over the next 4-5 weeks. 10 Tensile strength of a newly epithelialized wound is only 3% at 1 week, 20% after 3 weeks, and 80% after 3 months. The ultimate strength of the wound depends on both the quality and quantity of the collagen, 10 which is dependent on wound oxygenation. In summary, acute injury causes wound hypoxia that is magnified if there is pre-existing ischemia and hypoxia in the wound. Wound pO 2 further decreases as vessels thrombose in the hemostasis phase, leukocytes consume oxygen in the inflammatory phase, and fibroblasts consume oxygen in the proliferative phase. 30 Importantly, a healing wound has a higher metabolic demand than when it is in a steady state. This is evidenced by depression of wound-tissue pO 2 in the first few days after a major surgery. 30 Wound pO 2 is the rate limiting step in healing, especially in the acute postoperative phase, as the amount of O 2 extracted rises with increased oxygen breathing.
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Defining the chronic, problem wound A chronic wound can be defined as a wound that does not heal after an expected period of time. Chronic wounds are often trapped in the inflammatory phase of wound healing, unable to transition into the proliferative phase. Common causes for inflammation include infection, devitalized tissue that has been incompletely debrided, mechanical insults from retained foreign body or external pressure, and hypoxia as a result of wound ischemia. Initial efforts should focus on correcting or ruling out these causes of wound chronicity. We have enumerated many examples where tissue hypoxia can hinder wound healing.
Local tissue hypoxia may be caused by macrovascular disease with or without concomitant microvascular disease. Macrovascular status can be evaluated using ankle-brachial index, pulse volume recordings, arterial Doppler, computed tomography/magnetic resonance angiogram, and angiography. Presence of macrovascular disease should result in a vascular consultation to determine whether revascularization is possible. Microvascular disease may be evaluated using skin perfusion pressure, transcutaneous oxygen measurement (TCOM), and indocyanine green fluorescence angiography (ICGA).
TCOM is a non-invasive study that measures the pO 2 of tissue (TcPO 2 ) through intact skin. 31 This provides an In-chamber TcPO 2 was used to determine the appropriate treatment pressure for patients undergoing HBO 2 to treat lower extremity wounds. 35 The study used an inchamber TcPO 2 target of 250 mmHg for decision-making and demonstrated that nearly 80% of patients reached a TcPO 2 >250 mmHg at 2 ATA. For patients with a TcPO 2 <250 mmHg at 2 ATA, nearly half (41%) reached a TcPO 2 >250 mmHg when chamber pressure was increased to 2.4 ATA. This monoplace-based HBO 2 protocol allowed objective choice of treatment pressure that maximized benefit while minimizing risk.
35
ICGA is a newer technology that assesses microvascular skin perfusion using an intravenous injection of ICG followed by imaging with a near-infrared laser camera. It has been used extensively by surgeons in the operating room. 36 As opposed to breathing oxygen at sea-level atmospheric pressure, HBO 2 reduces ischemia-reperfusion (IR) injury, mobilizes circulating SPCs, enhances neutrophil bacterial killing activity, produces both reactive oxygen species (ROS) and reactive nitrogen species (RNS), and stimulates multiple growth factors that promote wound healing. 53 . NO is synthesized by three NO synthase enzymes: NOS-1 (nNOS), NOS-2 (iNOS), and NOS-3 (eNOS). Bone marrow eNOS activity is required for SPC mobilization -a function that is depressed in diabetic patients -and HBO 2 is able to stimulate eNOS activity, resulting in up-regulation of SPC production. 25, 49, 53, 57 Reactive species may have either positive or negative effects, depending on their concentration and intracellular localization. 60 A complete discussion of the role of ROS and RNS in wound healing is beyond the scope of this review, and readers are directed to Thom's manuscript for more details. 60 The body needs to balance the ROS that are generated as a part of normal metabolism with its natural anti-oxidant defenses. An inability to maintain balance results in oxidative stress, which can be seen where an overproduction of ROS in chronic wounds leads to a prolonged inflammatory state. A thorough summary and analysis of the hyperbaric literature regarding DFUs was published in 2017 84 and updated in 2019. 85 Readers are referred to these publications for a more in-depth discussion. Early studies showed that the use of HBO 2 was able to reduce the incidence of lower extremity amputation. Amputation rates decreased from 30%-40% without HBO 2 to only 5% with adjunctive HBO 2 .
86-89
Randomized controlled trials demonstrated that HBO 2 reduced the number of positive wound cultures, 90 and the integration of HBO 2 into a comprehensive limb salvage protocol has been advocated. 87, 113 DFUs remain the most common chronic wound type being treated with HBO 2 , but tightening requirements for reimbursement are constraining the frequency of its use. This may be wholly appropriate, given the rapid rise in outpatient wound and hyperbaric centers, 114 but there is a risk of denying limbsaving therapy to a patient who truly requires it.
Arterial insufficiency ulcers (AIUs)
Between 8-12 million people in the United States over 40 years of age are affected by PAD 115 and suffer tissue ischemia due to atherosclerosis. 116 AIUs are closely related to DFUs as the majority of patients with DFU also have PAD. These patients are often unable to be revascularized, leaving an above-ankle amputation as their only alternative. Healing rates with revascularization are reported between 50%-90% with amputation rates of <20%. 117, 118 Outcomes change dramatically without revascularization, however, with healing rates of 40%-50% and amputation rates between 25%-40%. 117, 118 HBO 2 reverses local tissue hypoxia and stimulates vasculogenesis, however it is less effective in the face of severe macrovascular disease. Inability to revascularize the lower extremity is not a reason to exclude HBO 2 from the treatment plan. A commonly overlooked aspect of the DFU studies previously mentioned is whether or not they include patients with underlying, uncorrectable vascular disease. While many wound healing studies excluded patients with significant PAD, the Faglia study included patients who had persistent tissue hypoxia and still showed increased healing and decreased amputation rates. 88 There are very few studies to guide patient selection for HBO 2 The evidence for the use of HBO 2 in the treatment of scleroderma relies on case reports of refractive scleroderma wounds that have healed with HBO 2 .
138-145
Patient selection should rely on clinical judgement as to the likelihood that HBO 2 can alter the trajectory of the scleroderma ulcer.
Graft-versus-host disease (GvHD)
Allogeneic stem cell transplantation in the treatment of hematopoietic and lymphatic malignancies may result in cutaneous complications of GvHD. The most common manifestations of GvHD are skin ulcers resulting from dermal/subcutaneous endothelial damage and microangiopathy.
146-148 HBO 2 results in neovascularization and collagen deposition at the site of hypoxic tissue such as those in GvHD. 24,53 HBO 2 may also play a role in immune modulation.
136,137
The evidence for use of HBO 2 in GvHD relies on animal studies and case report data. 149, 150 Patient selection should rely on clinical judgement and may benefit from objective assessments of tissue perfusion and hypoxia to determine whether treatment is appropriate for individual patients.
Pyoderma gangrenosum (PG)
PG is a rare neutrophilic dermatosis that affects the skin and subcutaneous tissues. Histopathologic characteristics include edema and neutrophil infiltrates of small and medium-sized vessels. Thrombosis of these vessels results in surrounding hemorrhage. The neutrophil infiltration and inflammation can result in abscess formation with resultant liquefaction of the tissue. 151 HBO 2 has been utilized for decades for the treatment of PG, [152] [153] [154] overcoming hypoxia and providing an antiinflammatory effect. A 2007 review provided a comprehensive listing of positive and negative case studies and concluded that HBO 2 was an effective treatment option for cutaneous ulcers related to PG, resulting in decreased pain and increased quality of life. 153 HBO 2 may be considered for PG ulcers refractive to conventional therapies.
Sickle cell disease (SCD)
SCD is characterized by red blood cells that deform and take a sickled shape, impairing binding of oxygen, compromising circulation, producing ischemia, and causing anemia. 155 Approximately 2.5% of patients with SCD will develop a lower extremity ulcer. 156 HBO 2 has been shown to reduce the percentage of circulating sickled cells after a hyperbaric exposure to 2 ATA. 157, 158 There is a single case report describing the use of HBO 2 for two patients with SCD-related cutaneous wounds with a 50% response rate. 159 There are both positive and negative case reports for the use of HBO 2 in the treatment of pain crises, 158, 160, 161 priapism, 162 and central retinal artery occlusion 163 complicated by SCD. There is insufficient evidence to support the routine use of HBO 2 in the treatment of SCD ulcers, although it may be useful for non-cutaneous manifestations of SCD.
Venous stasis ulcers (VLUs)
VLUs account for 90% of ulcers of the lower extremity and are the result of uncontrolled leg edema. Edema decreases perfusion as intra-compartment pressures rise and compromise capillary flow. Compression therapy is the mainstay of therapy, reducing edema through augmentation of the calf pump and directly increasing extraluminal pressure. With uncontrolled edema, oxygen diffusion from capillary beds is reduced as the distance between capillaries increases as a result of cellular tumescence. HBO 2 has been found to reduce wound surface area following therapy in two randomized, sham controlled trials, but neither showed an improvement in healing rates. 164, 165 A third study did show statistically significant wound healing with HBO 2 . 166 There is insufficient evidence to support the routine use of HBO 2 in the treatment of VLUs.
Conclusion
The use of HBO 2 for chronic, problem wounds is best defined for DFUs, but there is a sound fundamental basis for its use for some other chronic wound types. There is a lack of high-quality clinical evidence for non-DFU indications however, and providers must utilize clinical judgement to decide whether the reason for wound healing failure can be overcome with HBO 2 . Large clinical trials are unlikely to be successful given the rarity of these conditions, but participation in a research registry may allow pooled data to demonstrate efficacy of HBO 2 .
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